Exane BNP Paribas's Rating Change Only Had Short-term Impact, GlaxoSmithKline Up 1.3% (GSK)

Exane BNP Paribas downgraded GlaxoSmithKline (NYSE:GSK) from Neutral to Underperform a week ago. The stock closed at $43.06, which is 1.3% higher than the price one week ago ($42.51).GlaxoSmithKline...